Advanced Medical Solutions Grp PLC Full Year Trading Update (1492M)
January 10 2023 - 2:00AM
UK Regulatory
TIDMAMS
RNS Number : 1492M
Advanced Medical Solutions Grp PLC
10 January 2023
10 January 2023
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Full Year Trading Update - In Line with Expectations
Winsford, UK : Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies, today
announces its unaudited trading update for the year ended 31
December 2022 (the "Period").
The Group is pleased to report that trading for the Period was
strong as both Business Units continued to perform well. Group
revenues and profits for the Period are expected to be in line with
market expectations.
AMS also made good progress during 2022 in its regulatory and
clinical programmes including the US approval of LiquiBand(R) XL in
May and the submission of a PMA for LiquiBandFix8(R) in October.
The initial European SEAL-G(R) clinical trial also continues to
progress well with over two-thirds of patients now recruited and
remains on track for completion in the first half of this year.
The Group expects to announce its preliminary results on
Wednesday 15 March 2023.
Chris Meredith, Chief Executive Officer of AMS, commented : "I
am very pleased to report that AMS continued to perform strongly in
2022 despite the macro-economic challenges. This is a testament to
the resilience of our business model and the strength of our staff
who have worked so hard to achieve this result. The progress we
have made with our regulatory programmes is particularly
significant and represents a major step forward in our plan to gain
further traction in the US market. The underlying momentum
throughout the Group, which has been further strengthened with
promising new products, gives us confidence of meeting market
expectations for 2023 and sustaining our growth profile in the long
term."
- End -
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Matthew Neal / Lucy Featherstone
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence
HSBC Bank PLC (Broker) Tel: +44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a
patent-protected sealant technology platform; Biomatlante, an
established French developer and manufacturer of innovative
surgical biomaterial technologies, Raleigh, a UK leading coater and
converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, an Austrian a specialist
surgical business with a focus on minimally invasive
procedures.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany,
Austria, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Germany, France and Israel. Established
in 1991, the Group has more than 700 employees. For more
information, please see www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTDKLFBXFLBBBZ
(END) Dow Jones Newswires
January 10, 2023 02:00 ET (07:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024